Gynecologist

(TN) - Dr. Alpa M. Nick, MD

(TN) - Dr. Alpa M. Nick, MD

Dr. Nick is a board certified gynecologic oncologist. Dr. Nick received her medical degree from Louisiana State University Health Sciences Center, and completed her gynecologic oncology fellowship at the University of Texas MD Anderson Cancer Center in Houston, TX in 2011. As a gynecologic oncologist at MD Anderson Cancer Center, Dr. Nick worked collaboratively to expand the developmental therapeutics research program and led a quality improvement project focused on improving outcomes and standardizing care for patients with ovarian cancer. Dr. Nick provides patients who are high risk or have gynecologic cancers novel and up-to-date medical and surgical treatment options including laparoscopic and robotic surgery. 

(NY) - Dr. Mario M. Leitao, Jr., MD, FACOG, FACS

(NY) - Dr. Mario M. Leitao, Jr., MD, FACOG, FACS

I am a board-certified gynecologic oncologist who specializes in surgery for women with ovarian, endometrial, cervical, vulvar, or vaginal cancer.

I have a strong interest in providing minimally invasive surgical options for our patients, including both laparoscopic and robotic-assisted procedures. In 2006, I became one of the first gynecologic oncologists to use the da Vinci® Surgical System to perform robotically-assisted procedures in women with benign and malignant gynecologic conditions. Minimally invasive procedures result in less blood loss than do traditional surgeries, allowing for shorter hospital stays and faster recuperation time for patients. I serve as the Director for the Minimal Access and Robotic Surgery Program in the Department of Surgery at Memorial Sloan Kettering and have helped to build one of the best and most experienced robotic surgery programs in the world across multiple surgical specialties.

I also perform radical procedures via traditional laparotomy in cases when these more-traditional surgeries may provide better results and longer survival. These include debulking for ovarian cancer and radical procedures for other gynecologic cancers.

(MD) - Dr. Edward James Tanner, III, MD

(MD) - Dr. Edward James Tanner, III, MD

Dr. Edward Tanner is an assistant professor in the Johns Hopkins Medicine Department of Gynecology and Obstetrics and at Johns Hopkins Bayview Medical Center. He serves as the director of surgical innovations and the robotic surgery program in the department, leader of the Kelly Gynecologic Oncology Service’s Sentinel Lymph Node Program, and associate director of the F.J. Montz Fellowship Program in Gynecologic Oncology.

Additionally, Dr. Tanner is co-leader of the GYN/Urology Comprehensive Unit-based Safety Program and the Robotic Surgery Steering Committee. In these roles, he oversees a multidisciplinary program in surgical quality and patient safety at the hospital. Dr. Tanner is recognized for his outstanding surgical skills, compassionate bedside manner and teaching abilities.

Dr. Tanner’s clinical interests include the surgical management of advanced gynecologic cancers, including radical debulking surgery for ovarian cancer, as well as minimally invasive surgery for early-stage female cancers.

(CA) – Dr. Bridgette Duggan, MD

(CA) – Dr. Bridgette Duggan, MD

Biography

My practice is dedicated to the comprehensive care and treatment of women diagnosed with gynecologic cancers, pre-cancerous conditions and complex problems that require the specialized training and experience of a gynecologic oncologist.

It is the mission of our doctors, nurses and other support personnel to provide the best treatments available to all of our patients, while at the same time recognizing that each patient is a partner in their own treatment. We therefore strive to provide the highest level of care in an atmosphere that promotes the open exchange of information between the patient and the caregiver.

Even though the nature of medical care delivery changes daily, we will always work hard to maintain the high standard of patient care that has been a distinguishing feature of our practice since its beginning in 1998.

In practice since: 1992

(MN) - Dr. Jamie N. Bakkum-Gamez, MD

(MN) - Dr. Jamie N. Bakkum-Gamez, MD

The research involvement and interests of Jamie N. Bakkum-Gamez, M.D., include screening and early detection modalities in ovarian cancer and endometrial cancer; prognostic molecular markers in ovarian cancer and endometrial cancer; and quality improvement in postoperative outcomes after ovarian cancer staging surgery.

Dr. Bakkum-Gamez also focuses on prevention of ovarian cancer, fallopian tube cancer and primary peritoneal cancer, and is investigating minimally invasive surgical management of gynecologic cancers.

Additional research involves pathogenesis and risk factor modification in endometrial cancer.

(NC) - Dr. Paola A. Gehrig, MD

(NC) - Dr. Paola A. Gehrig, MD

Paola A. Gehrig, MD, is a UNC Lineberger Comprehensive Cancer Center member and Professor and Director of UNC Gynecologic Oncology within the Department of Obstetrics and Gynecology at UNC-Chapel Hill.

My clinical interests include gynecologic oncology, surgery in gynecologic malignancies, and complicated gynecologic surgery. 

My research interests include a range of clinical/translational research focused on women's cancers.

(AZ) - Dr. Janiel Cragun, MD

(AZ) - Dr. Janiel Cragun, MD

Dr. Cragun is an assistant professor at the University of Arizona. She specializes in the diagnosis and treatment of gynecologic cancers such as endometrial and ovarian cancers as well as rare reproductive cancers, abnormal pap smears, high-risk cancer screening and fertility preservation.

Before completing the gynecologic oncology fellowship program at the University of South Florida in Tampa, Dr. Cragun earned her medical degree at the University of Utah School of Medicine, Salt Lake City, Utah; completed a residency in obstetrics and gynecology at Duke University Medical Center, Durham, North Carolina, and pursued a post-doctoral research fellowship at H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.

Currently, gynecologic cancers account for about 12 percent of all cancers which affect US women.